Additionally, uliledlimab, a CD73-inhibiting antibody, in combination with atelizumab, has entered Phase II trials (NCT05001347) after demonstrating clinical activity in both PD-L1 treatment-naïve and refractory cancer patients with high archival tumor expression of CD73. This evidence concerns the gene NT5E and neoplasm.